Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,262.56 89.32 0.55%
S&P 500 1,842.98 12.37 0.68%
NASDAQ 4,034.16 11.47 0.29%
Ticker Volume Price Price Delta
STOXX 50 3,091.52 -40.05 -1.28%
FTSE 100 6,541.61 -42.15 -0.64%
DAX 9,173.71 -165.46 -1.77%
Ticker Volume Price Price Delta
NIKKEI 14,342.15 345.34 2.47%
TOPIX 1,159.82 23.73 2.09%
HANG SENG 22,813.92 142.66 0.63%

Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Catalyst Pharmaceutical Partners, Inc.



  Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of
  Catalyst Pharmaceutical Partners, Inc.

Business Wire

SAN DIEGO -- October 18, 2013

Shareholder rights law firm Johnson & Weaver, LLP has commenced an
investigation into whether certain officers and directors of Catalyst
Pharmaceutical Partners, Inc. (Nasdaq: CPRX) violated state or federal laws.

Catalyst Pharmaceutical shares were down over 25% on October 18, 2013 in early
morning trading. An article released prior to markets’ opening on October 18,
2013 by The Street discussed Catalyst’s drug Firdapse, which is currently in
trials. This article raised concerns that Catalyst investors may have bought
the Company’s shares with the belief that Firdapse is an up and coming orphan
drug. Catalyst shareholders may not be aware that there is a competing drug
made by Jacobus (3,4-Dap) that treats the same disease. Both drugs, Firdapse
and 3,4-Dap, treat Lambert-Eaton Myasthenic Syndrome (LEMS) -- a rare,
neuromuscular disease which causes progressive muscle weakness.

Jacobus (3,4-Dap), an equivalent drug to Firdapse, has been provided
to patients in the treatment of LEMS for over 20 years for free. Though
3,4-Dap has not been formally approved by the FDA, each free prescription of
the drug for the last 20 years has been approved by the FDA under a
"compassionate use" directive. Jacobus is now working to stop Catalyst from
gaining FDA approval for Firdapse in order to keep access free for LEMS
patients. To do so, Jacobus is now conducting a directly competitive clinical
trial with the intent of getting the drug formally approved by the FDA.

Johnson & Weaver’s investigation will seek to determine if investors were
previously misled by Catalyst Pharmaceutical officers or directors concerning
inadequate disclosure regarding Jacobus’ 3,4-Dap as a cost-free and effective
drug already in the marketplace.

If you have information that could assist in this investigation, or if you are
an Catalyst Pharmaceutical shareholder and are interested in learning more
about the investigation or your legal rights and remedies, please contact Jim
Baker (jimb@johnsonandweaver.com) by email or by phone at 619-230-0063, Ext.
118.

Johnson & Weaver, LLP is a nationally recognized shareholders’ rights law
firm. The firm represents individual and institutional investors in
shareholder derivative and securities class action lawsuits. For more
information about the firm and its attorneys, please visit
http://www.johnsonandweaver.com.

Contact:

Johnson & Weaver, LLP
Jim Baker, 619-230-0063 Ext. 118
jimb@johnsonandweaver.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement